February 2nd, 2015
This week’s topics include less-tight vs. tight hypertension control in pregnancy, icatibant for ACE-inhibitor-induced angioedema, and more.
September 29th, 2014
Clyde Yancy and Mary Norine Walsh offer their perspectives on the much-discussed PARADIGM-HF trial.
September 5th, 2014
The Editors present a distillation of reader comments on a popular post.
September 1st, 2014
Vinay Prasad explores three reasons why clinicians should have reservations about the findings from PARADIGM-HF.
August 30th, 2014
John J.V. McMurray and Milton Packer, the two lead authors of the PARADIGM-HF trial, discuss the randomized comparison of angiotensin–neprilysin inhibition with the ACE inhibitor enalapril.
August 28th, 2014
Larry Husten analyzes the expectations surrounding the upcoming release of PARADIGM-HF and its centerpiece LCZ696 from the perspective of the medical field as well as the world of economics.
November 18th, 2013
This week’s topics include the VA-NEPHRON-D and IABP-SHOCK II trials, a study of the sex differences in ACS symptoms among young patients, and more.
October 22nd, 2013
Although taught in medical school and widely used in clinical practice, broad screening of otherwise healthy people for chronic kidney disease (CKD) is unwarranted, according to new recommendations from the American College of Physicians published in the Annals of Internal Medicine. People with early kidney disease, who are classified as having stages 1 to 3 CKD, usually […]
July 29th, 2013
An observational study from Ireland raises the intriguing possibility that centrally acting ACE inhibitors may help slow the cognitive decline that is a hallmark of people with Alzheimer’s disease and other forms of dementia. The study, published in BMJ Open, followed the rates of cognitive decline in 3 groups of patients: dementia patients being treated with centrally acting ACE inhibitors, […]
February 5th, 2013
Giving an ACE inhibitor to people with peripheral artery disease (PAD) and intermittent claudication reduces pain and increases walking time, according to a new study published in JAMA. Currently the pharmacologic options for this patient population are few and have limited efficacy. Researchers at three Australian hospitals randomized 212 patients with PAD to receive the ACE inhibitor ramipril or placebo for 24 […]